Caris Life Sciences Inc. (CAI)
NASDAQ: CAIHealth CareMedical SpecialitiesUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 27.10 0.00%
CAI stock chart
Technical analysisKey statistics
All statistics- Market cap
- $7.66B
- P/E (TTM)
- 16.04
- Forward P/E
- 73.60
- EPS (TTM)
- $1.69
- Dividend yield
- None
- 52-week range
- 14.19 – 33.65
- Day range
- 26.07 – 27.56
- Volume / Avg
- 4.87M / 4.90M
- Beta
- —
- Shares outstanding
- 282.68M
- Next earnings
- Nov 4, 2026
52-week range
CAI stock today
Caris Life Sciences (CAI) closed at $27.10 on Oct 7, down 1.29% (-$0.355), versus the S&P 500's 0.22% decline. Shares are 19.5% below their 52-week high of $33.65, set on Oct 7, 2025 and 91.0% above the 52-week low of $14.19, in the middle of the past year's range. CAI is up 0.4% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 14.2%.
At 16.0x trailing earnings, Caris Life Sciences trades below the peer-group median of 25.5x. Its forward P/E of 73.6x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year. Caris Life Sciences's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Caris Life Sciences
Company profileCaris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers.
- Sector
- Health Care
- Industry
- Medical Specialities
- CEO
- Dr. David Dean Halbert M.D.
- Headquarters
- Irving, TX
- Employees
- 1,846
- IPO year
- 2025
- Website
- carislifesciences.com
Financial highlights
Full financialsIn fiscal 2025, Caris Life Sciences generated $812.0 million in revenue, up 97.0% from fiscal 2024, its 2nd consecutive year of revenue growth. Caris Life Sciences reported a net loss of $68.1 million, compared with a loss of $281.9 million a year earlier. Operating margin was 5.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | $812.03M | $412.26M | $306.13M |
| Growth | +96.97% | +34.67% | — |
| Net income | $-68.09M | $-281.89M | $-341.42M |
| EPS (diluted) | $-3.22 | $-10.66 | $-13.24 |
Analyst forecast
ForecastConsensus (14 analysts)
buy
Avg. price target
$29.08+7.31%
- Strong buy 1
- Buy 9
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $0.03
- Last reported (Q2 2026)
- Aug 5, 2026
- EPS actual vs est.
- $0.00 vs —
Caris Life Sciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| HSICHenry Schein Inc. | 83.66 | -1.39% | $9.32B | vs CAI |
| GRALGRAIL Inc. | 132.90 | -3.19% | $5.94B | vs CAI |
| RDNTRadNet Inc. | 68.61 | -2.38% | $5.40B | vs CAI |
| OSCROscar Health Inc. Class A | 32.91 | +1.76% | $10.16B | vs CAI |
| MOHMolina Healthcare Inc | 194.82 | -0.18% | $10.17B | vs CAI |
| CONConcentra Group Holdings Parent Inc. | 36.40 | 0.00% | $4.64B | vs CAI |
| BLLNBillionToOne Inc. Class A | 95.75 | -4.19% | $4.52B | vs CAI |
| VCYTVeracyte Inc. | 43.16 | -3.34% | $3.47B | vs CAI |
Indexes, lists and sector
Caris Life Sciences stock FAQ
What is Caris Life Sciences's stock price today?
CAI last traded at $27.10 as of Oct 7, 4:00 PM EDT, down 1.29% on the day. Prices are delayed at least 15 minutes.
When is Caris Life Sciences's next earnings date?
Caris Life Sciences is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $0.03.
What is CAI's P/E ratio?
CAI trades at a trailing P/E ratio of 16.04 and a forward P/E of 73.60, compared with a median of 25.5 for its closest peers.
Who is Caris Life Sciences's CEO?
Dr. David Dean Halbert M.D. is the chief executive officer of Caris Life Sciences Inc., which has about 1,846 employees.
What is the CAI 52-week high?
The 52-week high for CAI is $33.65 and the 52-week low is $14.19. The stock is currently 19.5% below its high.